Merck & Co., Inc. (NYSE:MRK) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 20, 2026, Citi raised the price target on Merck & Co., Inc. (NYSE:MRK) to $125 from $120 and maintained a Neutral rating. On March 18, 2026, Merck’s Animal Health division announced that the FDA approved an expanded label for Bravecto Quantum in dogs, adding treatment and control for additional tick species for up to 12 months with a single injection. The product, first approved in July 2025, remains availab ...